Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $3.4M | $13.3M | $22.3M | $18.8M | $38.7M | $19.8M | $57.3M |
| Cost of revenue | $423.0K | $9.5M | $30.2M | $50.5M | $93.0M | $6.7M | $7.8M | $6.9M |
| Gross profit | $1.5M | −$6.1M | −$16.9M | −$28.2M | −$74.1M | $32.0M | $12.0M | $50.4M |
| Gross margin | 77.5% | -179.4% | -127.3% | -126.8% | -393.3% | 82.7% | 60.5% | 87.9% |
| R&D | $16.6M | $9.5M | $30.2M | $50.5M | $93.0M | $84.7M | $82.4M | $48.9M |
| Operating income | −$24.4M | −$17.8M | −$31.0M | −$70.4M | −$100.8M | −$80.1M | −$88.9M | −$10.5M |
| EBITDA | −$10.6M | −$22.1M | −$28.3M | −$66.0M | −$99.0M | −$72.9M | −$80.1M | $1.2M |
| Net income | −$11.0M | −$23.1M | −$30.3M | −$69.4M | −$104.9M | −$83.0M | −$92.7M | −$8.1M |
| Net margin | -586.6% | -681.6% | -228.0% | -311.7% | -556.7% | -214.5% | -469.4% | -14.2% |
| EPS (diluted) | -55.58 | -31.65 | -15.35 | -27.62 | -33.06 | -22.50 | -24.75 | -1.80 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $27M | $-40.95 | $-40.95–$-40.95 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds MTEM.
No tracked institution reports a position in MTEM as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-08-14 | 1-for-15reverse |
No one on the platform has traded MTEM yet.
| $566 |
| — |
| EPRSQEPIRUS Biopharmaceuticals, Inc. | $0.00 | -99.00% | $1571 | — |
| IMVIQIMV Inc. | $0.00 | -90.00% | $117 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.0× sales vs its 4.2× historical median P/S.
Fair value ≈ $55.99 · price $0.00 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$AEMD low float bio related to Ebola $TWG low float recent acquisition w 125mln$ target and huge spike to 20$ $MTEM going
View on StockTwits ↗$VSME banked 120% gain $MTEM next one $TWG buying bc will be same like vsme
View on StockTwits ↗$TWG Hevi guys look at this float $VSME $MTEM
View on StockTwits ↗$KRKR today is the day? Give me 20$ $INHD $CHAI $MTEM
View on StockTwits ↗$PAVS. Just bought 2K Shares to help us get over this selling wall. Buy and hold, We moon together.. $MTEM $CCTG . We 🚀🚀🚀 together
View on StockTwits ↗$CCTG Stope selling and we'll break the wall. Too many sellers giving there shares away for pennies. $PAVS $MTEM
View on StockTwits ↗$KRKR this is the most attractive chart to me. Fundamentals, low float, history of big spikes. One day this chat will be very busy. Get a seat 💺 and stay with all my team. $INHD $CCTG $MTEM —$PAVM
View on StockTwits ↗$MTEM the whole bunch employed, or was once employed here are a bunch of fuckin losers
View on StockTwits ↗$MTEM Molecular Templates (OTC:MTEMQ), Inc., a pharmaceutical company, has voluntarily filed for Chapter 11 bankruptcy protection as of Sunday, April 20, 2025
View on StockTwits ↗$MTEM ETB platform looks promising. Watching MT-6402 trial results closely. Potential game-changer in cancer treatment. Might start small position if next data drop looks solid. detailed article: https://beyondspx.com/article/molecular-templates-mtem-pioneering-targeted-biologics-for-cancer-and-immune-disorders
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.